Verity focuses on specialty pharmaceuticals that are well entrenched in treatment protocols and in demand by physicians, for their patients. We are currently in the process of filing several drug dossiers with Health Canada in the following areas:
Health Canada has authorized the sale of this COVID-19 vaccine under an Interim Order (IO). Find out more about COVISHIELD™ at www.covishield-canada.ca or consult the product monograph by clicking this link: COVISHIELD™ Product Monograph.
IVOZFO™(fosfomycin for injection) is a hospital based intravenous antimicrobial agent targeted at the treatment of hard to treat and multi-drug resistant bacterial infections and is approved for use in the Canadian hospital environment. For important information concerning IVOZFO please visit www.ivozfo.com or consult the product monograph by clicking this link: IVOZFO™(fosfomycin for injection) Product Monograph.
Verity is also investigating other therapeutically relevant products within the infectious disease category.
VERITY‑BCG™ is an adjuvant therapy after transurethral resection of the bladder (TURB). It is prescribed as first-line intravesical therapy following tumor resection of non–muscle-invasive bladder cancer. The introduction of VERITY‑BCG™ will help to alleviate the BCG shortage that Canada has been facing due to ongoing global supply constraints.
Bladder cancer is the 5th most common cancer in Canada and almost 12,000 people will be diagnosed with bladder cancer this year alone. Intravesical immunotherapy with BCG is a treatment that boosts the ability of the immune system to fight the cancer. Patients treated with optimal BCG treatment regimens are more likely to have a long-term reduction in tumor recurrence, tumor progression and cancer mortality.
For more information about VERITY‑BCG™ please consult the product monograph by clicking this link: Verity‑BCG (Bacillus Calmette-Guérin [BCG]: Strain Russian BCG-I).
Zeulide Depot (leuprolide acetate for depot suspension) is a luteinizing hormone-releasing hormone agonist (LHRHa) and is prescribed for the treatment of prostate cancer. 1 in 9 Canadian men will be diagnosed with prostate cancer in their lifetime. Many will be prescribed a LHRHa therapy, the treatment of choice for physicians in North America and Europe. With clinically validated efficacy and an innovative microsphere controlled-release technology, Zeulide Depot will offer an effective option for physicians and their patients and will also be the most cost-effective prostate cancer therapy in Canada. For important information concerning Zeulide Depot please visit www.zeulidedepot.com or consult the product monograph by clicking this link: Zeulide Depot (leuprolide acetate for depot suspension) Product Monograph.
Verity will also be launching another antineoplastic agent used in the treatment of adenocarcinomas and other numerous cancers. We are currently discussing the regulatory pathway of our drug dossier with Health Canada.
Verity has licensed the oral fertility drug Clomiphene Citrate for re-introduction to the Canadian healthcare community. Physicians and patients have expressed their desire to regain access to this clinically effective and safe fertility product.
Verity will be launching a diagnostic agent for use in genitourinary surgery. Currently, the regulatory pathway with our drug dossier for Health Canada is being developed and finalized.
Verity will also be launching two therapeutically relevant ophthalmic products and is looking into several other opportunities as we continue towards development of a solid Ophthalmology portfolio.
Verity is actively negotiating with global pharmaceutical companies on in-licensing targeted agents that our scientific advisory board have identified as therapeutically relevant and have undergone short supply or are at risk of being in short supply in the Canadian market.